Nonhuman Primate Models of Stroke for Translational Neuroprotection Research

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 371-379

  Cook, Douglas J ^a   Tymianski, Michael ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Clinical trials; Macaque; Models of disease; Nonhuman primate; Stroke; Translational research

Indexed keywords

ANATOMICAL CONCEPTS; AOTUS; AOTUS LEMURINUS; BASAL GANGLION; BIOETHICS; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN MAPPING; CALLITHRIX JACCHUS; CALLITRICHINAE; CAPSULA INTERNA; CELL DEATH; CHLOROCEBUS; COGNITION; DISEASE MODEL; EXPERIMENTAL ANIMAL; FEASIBILITY STUDY; GALAGIDAE; GALAGO SENEGALENSIS; GLUCOSE BLOOD LEVEL; GRAY MATTER; LEARNING; MACACA; MACACA FASCICULARIS; MACACA FUSCATA; MACACA MULATTA; MEMORY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN SATURATION; PAPIO ANUBIS; PH; PRIMATE; PRIORITY JOURNAL; REVIEW; SAIMIRI SCIUREUS; SQUIRREL MONKEY; STROKE; WHITE MATTER;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEUROPROTECTIVE AGENTS; PRIMATES; SPECIES SPECIFICITY; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84859710534     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0115-z     Document Type: Review

References (73)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.
2. Zorowitz RD, Chen E, Tong KB, Laouri M. Costs and rehabilitation use of stroke survivors: a retrospective study of Medicare beneficiaries. Top Stroke Rehabil 2009; 16: 309-320.
3. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-2136.
4. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-1020.
5. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415.
6. Lo EH. Degeneration and repair in central nervous system disease. Nat Med 2010; 16: 1205-1209.
7. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001; 32: 1349-1359.
8. O'Collins VE, Macleod MR, Donnan GA, et al. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-477.
9. Cook DJ, Tymianski M. Translating promising preclinical neuroprotective therapies to human stroke trials. Expert Rev Cardiovasc Ther 2011; 9: 433-449.
10. Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005; 2: 396-409.
11. Fisher M, Finklestein S. Pharmacological approaches to stroke recovery. Cerebrovasc Dis 1999; 9(suppl 5): 29-32.
12. Howells DW, Porritt MJ, Rewell SS, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab 2010; 30: 1412-1431.
13. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
14. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250.
15. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007; 205: 20-25.
16. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26: 1465-1478.
17. Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke 2009; 40: 577-581.
18. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289-1292.
19. NINDS tSTSG. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
20. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003; 34: 2228-2233.
21. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001; 32: 190-198.
22. Marshall JW, Green AR, Ridley RM. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res 2003; 972: 119-126.
23. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-571.
24. Rossi J. Nonhuman primate research: the wrong way to understand needs and necessity. Am J Bioeth 2009; 9: 21-23.
25. Sughrue ME, Mocco J, Mack WJ, et al. Bioethical considerations in translational research: primate stroke. Am J Bioeth 2009; 9: 3-12.
26. Wilkinson D. Trade-offs in suffering and wellbeing: the utilitarian argument for primate stroke research. Am J Bioeth 2009; 9: 19-21.
27. Tagaya M, Liu KF, Copeland B, et al. DNA scission after focal brain ischemia. Temporal differences in two species. Stroke 1997; 28: 1245-1254.
28. Nudo RJ, Larson D, Plautz EJ, et al. A squirrel monkey model of poststroke motor recovery. ILAR J 2003; 44: 161-174.
29. Marshall JW, Ridley RM. Assessment of cognitive and motor deficits in a marmoset model of stroke. ILAR J 2003; 44: 153-160.
30. Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab 2008; 28: 1877-1891.
31. Murphy SJ, McCullough LD, Smith JM. Stroke in the female: role of biological sex and estrogen. ILAR J 2004; 45: 147-159.
32. Graham SM, McCullough LD, Murphy SJ. Animal models of ischemic stroke: balancing experimental aims and animal care. Comp Med 2004; 54: 486-496.
33. Nehls DG, Cartwright M, Spetzler RF. Experimental primate stroke model. Neurosurgery 1986; 18: 388-389.
34. Spetzler RF, Zabramski JM, Kaufman B, Yeung HN. Acute NMR changes during MCA occlusion: a preliminary study in primates. Stroke 1983; 14: 185-191.
35. Mack WJ, Komotar RJ, Mocco J, et al. Serial magnetic resonance imaging in experimental primate stroke: validation of MRI for pre-clinical cerebroprotective trials. Neurol Res 2003; 25: 846-852.
36. Huang J, Mocco J, Choudhri TF, et al. A modified transorbital baboon model of reperfused stroke. Stroke 2000; 31: 3054-3063.
37. D'Ambrosio AL, Sughrue ME, Mocco J, et al. A modified transorbital baboon model of reperfused stroke. Methods Enzymol 2004; 386: 60-73.
38. Del Zoppo GJ, Copeland BR, Harker LA, et al. Experimental acute thrombotic stroke in baboons. Stroke 1986; 17: 1254-1265.
39. Mack WJ, King RG, Hoh DJ, et al. An improved functional neurological examination for use in nonhuman primate studies of focal reperfused cerebral ischemia. Neurol Res 2003; 25: 280-284.
40. Roitberg B, Khan N, Tuccar E, et al. Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol Res 2003 Jan; 25: 68-78.
41. Murphy SJ, Kirsch JR, Zhang W, et al. Can gender differences be evaluated in a rhesus macaque (Macaca mulatta) model of focal cerebral ischemia? Comp Med 2008; 58: 588-596.
42. Takamatsu H, Tsukada H, Kakiuchi T, et al. Detection of reperfusion injury using PET in a monkey model of cerebral ischemia. J Nucl Med 2000; 41: 1409-1416.
43. West GA, Golshani KJ, Doyle KP, et al. A new model of cortical stroke in the rhesus macaque. J Cereb Blood Flow Metab 2009; 29: 1175-1186.
44. Hirouchi Y, Suzuki E, Mitsuoka C, et al. Neuroimaging and histopathological evaluation of delayed neurological damage produced by artificial occlusion of the middle cerebral artery in Cynomolgus monkeys: establishment of a monkey model for delayed cerebral ischemia. Exp Toxicol Pathol 2007; 59: 9-16.
45. Furuichi Y, Katsuta K, Maeda M, et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res 2003; 965: 137-145.
46. Li HL, Yan C, Li J, et al. Seroprevalence of Toxoplasma gondii in bred cynomolgus monkeys (Macaca fascicularis) in China. J Parasitol 2010; 96: 807-808.
47. Yoshikawa T, Akiyoshi Y, Susumu T, et al. Ginsenoside Rb1 reduces neurodegeneration in the peri-infarct area of a thromboembolic stroke model in nonhuman primates. J Pharmacol Sci 2008; 107: 32-40.
48. Kito G, Nishimura A, Susumu T, et al. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods 2001; 30; 105: 45-53.
49. Kuge Y, Yokota C, Tagaya M, et al. Serial changes in cerebral blood flow and flow-metabolism uncoupling in primates with acute thromboembolic stroke. J Cereb Blood Flow Metab 2001; 21: 202-210.
50. Qureshi AI, Suri MF, Ali Z, et al. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a nonhuman primate model. Neuroradiology 2005; 47: 845-854.
51. de Crespigny AJ, D'Arceuil HE, Maynard KI, et al. Acute studies of a new primate model of reversible middle cerebral artery occlusion. J Stroke Cerebrovasc Dis 2005; 14: 80-87.
52. Yonas H, Wolfson SK, Jr., Dujovny M, Boehnke M, Cook E. Selective lenticulostriate occlusion in the primate. A highly focal cerebral ischemia model. Stroke 1981; 12: 567-572.
53. Hamberg LM, Hunter GJ, Maynard KI, et al. Functional CT perfusion imaging in predicting the extent of cerebral infarction from a 3-hour middle cerebral arterial occlusion in a primate stroke model. AJNR Am J Neuroradiol 2002; 23: 1013-1021.
54. D'Arceuil HE, Duggan M, He J, Pryor J, de Crespigny A. Middle cerebral artery occlusion in Macaca fascicularis: acute and chronic stroke evolution. J Med Primatol 2006; 35: 78-86.
55. Marshall JW, Ridley RM. Assessment of functional impairment following permanent middle cerebral artery occlusion in a nonhuman primate species. Neurodegeneration 1996; 5: 275-286.
56. Kwon S, Hartzema AG, Duncan PW, Min-Lai S. Disability measures in stroke: relationship among the Barthel Index, the functional independence measure, and the modified rankin scale. Stroke 2004; 35: 918-923.
57. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med 1975; 7: 13-31.
58. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res 1981; 4: 483-492.
59. Palfi S, Conde F, Riche D, et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 1998; 4: 963-966.
60. Dorman PJ, Sandercock PA. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 1996; 27: 1507-1515.
61. Fuster JM. Unit activity in prefrontal cortex during delayed-response performance: neuronal correlates of transient memory. J Neurophysiol 1973; 36: 61-78.
62. Zola-Morgan S, Squire LR. Preserved learning in monkeys with medial temporal lesions: sparing of motor and cognitive skills. J Neurosci 1984; 4: 1072-1085.
63. Herndon JG, Moss MB, Rosene DL, Killiany RJ. Patterns of cognitive decline in aged rhesus monkeys. Behav Brain Res 1997; 87: 25-34.
64. Moore TL, Killiany RJ, Herndon JG, Rosene DL, Moss MB. Impairment in abstraction and set shifting in aged rhesus monkeys. Neurobiol Aging 2003; 24: 125-134.
65. Moss MB, Jonak E. Cerebrovascular disease and dementia: a primate model of hypertension and cognition. Alzheimers Dement 2007; 3(2 suppl): S6-S15.
66. Johnston K. What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 1999; 18: 167-173.
67. Saver JL, Johnston KC, Homer D, et al. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke 1999; 30: 293-298.
68. Hoehn-Berlage M, Eis M, Back T, Kohno K, Yamashita K. Changes of relaxation times (T1, T2) and apparent diffusion coefficient after permanent middle cerebral artery occlusion in the rat: temporal evolution, regional extent, and comparison with histology. Magn Reson Med 1995; 34: 824-834.
69. Jokivarsi KT, Hiltunen Y, Tuunanen PI, Kauppinen RA, Grohn OH. Correlating tissue outcome with quantitative multiparametric MRI of acute cerebral ischemia in rats. J Cereb Blood Flow Metab 2010; 30: 415-427.
70. Bederson JB, Pitts LH, Germano SM, et al. Evaluation of 2, 3, 5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986; 17: 1304-1308.
71. Murakami Y, Takamatsu H, Noda A, et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J Nucl Med 2004; 45: 1946-1949.
72. Yanagihara T. Experimental stroke in gerbils: effect on translation and transcription. Brain Res 1978; 158: 435-444.
73. Kharlamov A, LaVerde GC, Nemoto EM, et al. MAP2 immunostaining in thick sections for early ischemic stroke infarct volume in nonhuman primate brain. J Neurosci Methods 2009; 182: 205-210.